MPMatthew G. Parry

Matthew G. Parry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew G. Parry has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Heather Payne

    Department of Oncology University College London Hospitals London UK

    20 shared publications
  • Noel W. Clarke

    Department of Urology The Christie and Salford Royal Hospitals Manchester UK

    20 shared publications
  • Ajay Aggarwal

    Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine London UK

    19 shared publications
  • Jan van der Meulen

    National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK; Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK

    17 shared publications
  • Paul Cathcart

    Department of Urology, Guy's & St Thomas' NHS Foundation Trust, UK

    16 shared publications
  • Arunan Sujenthiran

    The National Prostate Cancer Audit, Clinical Effectiveness Unit Royal College of Surgeons of England London UK

    15 shared publications

Latest Publications

  • Open Access

    Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study

    by Arjun Nathan, Matthew G. Parry, Emily Mayne, Adrian Cook, Justin Liu, Raghav Varma, Will Cuningham, Joanna Dodkins, Marina Parry, Julie Nossiter, et al.

  • Open Access

    Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer

    by Matthew G Parry, Anissa V Bailey, Thomas R Belin, David Elashoff, Claire Foster, Ian Graham, Christoph Kowalski, Lorna Kwan, Jeremy Millar, Nora Tabea Sibert, et al.

    Background: Urinary and sexual function are impacted by prostate cancer treatment but also by comorbidities. We aimed to report the impact of comorbidities on functional outcomes after prostate cancer treatment. Methods: We used patient reported EPIC-26, at baseline and 12 months, from a multicenter, prospective international cohort. Forest plots were constructed for urinary and sexual function, according to treatment, age and comorbidities (heart disease, hypertension and diabetes mellitus). Results: We identified 10,928 patients diagnosed with non-metastatic prostate cancer with complete PROMs at baseline and at 12 months. Urinary and sexual function at baseline varied with age and comorbidities, but the biggest impact on 12-month function was the treatment itself. Surgery had a greater impact on urinary function compared to radiotherapy, irrespective of comorbidities, but this was only observed for sexual function in those with no comorbidities. Men of younger age and those with no comorbidities had the best preservation of urinary and sexual function after treatment, but a floor effect was observed whereby those with better baseline sexual function reported larger post-treatment differences. Conclusions: The impact of age and comorbidity on functional outcomes after prostate cancer treatment is minimal when considered against the impact of the treatment itself.


  • Open Access

    Characteristics and outcomes of men presenting with complications of metastatic prostate cancer

    by Arjun Nathan, Matthew G. Parry, Adrian Cook, Emily Mayne, Joanna Dodkins, Marina Parry, Raghav Varma, Ajay Aggarwal, Jan van der Meulen, James S. A. Green, et al.

    Objectives: To describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under‐reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal‐related events (SREs), collectively termed ‘metastatic‐related events’ (MREs). Patients and Methods: We used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer‐specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination). Results: Of 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70–79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77–0.88) and men aged 60–69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84–0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15–1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5‐year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2–58.4%), compared to 77.1% (95% CI 74.9–79.2%) with MUO, 66.8% (95% CI 64.1–69.4%) with a SRE and 84.4% (95% CI 74.1–94.7%) with both. Conclusions: The risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.


  • Open Access

    Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England

    by Joanna Dodkins, Adrian Cook, Emily Mayne, Marina Parry, Matthew G. Parry, Jemma Boyle, Julie Nossiter, Thomas E. Cowling, Alison Tree, Noel Clarke, et al.


  • Reply to: Letter to the editor regarding the article ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’

    by Matthew G. Parry, Arunan Sujenthiran, Julie Nossiter, Melanie Morris, Brendan Berry, Arjun Nathan, Ajay Aggarwal, Heather Payne, Jan van der Meulen, Noel W. Clarke

  • Open Access

    Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound

    by Matthew G. Parry, Arunan Sujenthiran, Julie Nossiter, Melanie Morris, Brendan Berry, Arjun Nathan, Ajay Aggarwal, Heather Payne, Jan van der Meulen, Noel W. Clarke

    Objective: To report the 5‐year failure‐free survival (FFS) following high‐intensity focused ultrasound (HIFU). Patients and Methods: This observational cohort study used linked National Cancer Registry data, radiotherapy data, administrative hospital data and mortality records of 1381 men treated with HIFU for clinically localised prostate cancer in England. The primary outcome, FFS, was defined as freedom from local salvage treatment and cancer‐specific mortality. Secondary outcomes were freedom from repeat HIFU, prostate cancer‐specific survival (CSS) and overall survival (OS). Cox regression was used to determine whether baseline characteristics, including age, treatment year, T stage and International Society of Urological Pathology (ISUP) Grade Group were associated with FFS. Results: The median (interquartile range [IQR]) follow‐up was 37 (20–62) months. The median (IQR) age was 65 (59–70) years and 81% had an ISUP Grade Group of 1–2. The FFS was 96.5% (95% confidence interval [CI] 95.4%–97.4%) at 1 year, 86.0% (95% CI 83.7%–87.9%) at 3 years and 77.5% (95% CI 74.4%–80.3%) at 5 years. The 5‐year FFS for ISUP Grade Groups 1–5 was 82.9%, 76.6%, 72.2%, 52.3% and 30.8%, respectively ( P < 0.001). Freedom from repeat HIFU was 79.1% (95% CI 75.7%–82.1%), CSS was 98.8% (95% CI 97.7%–99.4%) and OS was 95.9% (95% CI 94.2%–97.1%) at 5 years. Conclusion: Four in five men were free from local salvage treatment at 5 years but treatment failure varied significantly according to ISUP Grade Group. Patients should be appropriately informed with respect to salvage radical treatment following HIFU.


  • Open Access

    Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study

    by Arunan Sujenthiran, Matthew G. Parry, Joanna Dodkins, Julie Nossiter, Melanie Morris, Brendan Berry, Arjun Nathan, Paul Cathcart, Noel W. Clarke, Heather Payne, et al.


  • Open Access

    A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer

    by Christian D. Fankhauser, Matthew G. Parry, Adnan Ali, Thomas E. Cowling, Julie Nossiter, Arun Sujenthiran, Brendan Berry, Melanie Morris, Ajay Aggarwal, Heather Payne, et al.


  • Interventions for obstructive uropathy in advanced prostate cancer: a population‐based study

    by Arjun Nathan, Melanie Morris, Matthew G. Parry, Brendan Berry, Arunan Sujenthiran, Julie Nossiter, Heather Payne, Jan Van Der Meulen, Noel W. Clarke, James S. A. Green

    Objectives: To develop and validate a coding framework to identify interventions for upper tract obstructive uropathy (UTOU) in men with locally advanced and metastatic prostate cancer (PCa) using administrative hospital data to assess clinical outcomes. There are no population‐based studies on the incidence, treatment, and outcomes of this complication. Patients and Methods: Patients newly diagnosed with PCa between April 2014 and March 2019 were identified in the English cancer registry. A coding framework based on procedure (Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures fourth edition) and diagnostic (International Classification of Diseases, 10th edition) codes was developed and validated. Subsequent clinical outcomes were determined using Hospital Episodes Statistics to determine the utility of the intervention. Results: A total of 77 010 patients newly diagnosed with locally advanced, and 30 083 patients with metastatic PCa were identified. Of these, 1951 (1.8%) patients underwent an intervention for UTOU according to our coding framework: 830 (42.5%) had locally advanced disease and 1121 (57.5%) had metastatic disease. In all, 844 (43.3%) had a percutaneous nephrostomy (PCN), 473 (24.2%) had a PCN with antegrade stent, and 634 (32.5%) had a retrograde stent. The mean follow‐up was 43.2 months. The cumulative incidence of the use of these interventions at 1, 3, and 5 years was 2.5%, 3.6% and 4.2% in men with metastases compared to 0.5%, 0.9% and 1.4% in men with locally advanced disease. Conclusion: A new coding framework, developed to identify procedures for UTOU was applied in the largest study to date of UTOU in men with primary locally advanced and metastatic PCa. Results demonstrated that 2% of men with locally advanced PCa and 4% of men with metastatic PCa require an intervention to resolve UTOU within 5 years of their PCa diagnosis.


  • Implementation of patient-reported outcome measures into health care for men with localized prostate cancer

    by Udit Singhal, Ted A. Skolarus, John L. Gore, Matthew G. Parry, Ronald C. Chen, Julie Nossiter, Alan Paniagua-Cruz, Arvin K. George, Paul Cathcart, Jan van der Meulen, et al.

    Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.